Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Adjuvant Therapy for Incidental SCLC
NCT07097948Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Aug 2025
- Primary completion
- Jul 2030
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in small cell lung cancer (SCLC), sponsored by Shanghai Pulmonary Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07097948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07097948.